Researchers at Mount Sinai School of Medicine have determined people who were vaccinated against the 2009 H1N1 influenza virus may also be protected against the lethal 1918 Spanish influenza virus, which killed more than 50 million people worldwide. The new findings are published in the current issue of Nature Communications.
"While the reconstruction of the formerly extinct Spanish influenza virus was important in helping study other pandemic viruses, it raised some concerns about an accidental lab release or its use as a bioterrorist agent," said Adolfo Garcia-Sastre, PhD, professor of microbiology at Mount Sinai School of Medicine, and lead investigator on the study. "Our research shows that the 2009 H1N1 influenza vaccine protects against the Spanish influenza virus, an important breakthrough in preventing another devastating pandemic like 1918." Other Mount Sinai School of Medicine groups involved in the study include the laboratories of Dr. Palese and Dr. Basler. The study was also done in collaboration with the group of Dr. Belshe, at St. Louis University, who provided the human vaccination samples.
The researchers administered to three groups of mice either the 2009 H1N1 influenza vaccine, the seasonal influenza vaccine, or no vaccine at all. Twenty-one days later, the mice were exposed to a lethal dose of the 1918 Spanish influenza virus. The mice receiving the H1N1 vaccine were the only ones to survive, while also exhibiting limited morbidity following the vaccination.
Additionally, Dr. Garcia-Sastre's team injected the mice with blood serum taken from humans who had been vaccinated against 2009 H1N1 influenza. Later, the mice were given a potent dose of the 1918 Spanish influenza virus. Researchers found that the antibodies in the blood produced by the 2009 H1N1 vaccine may also protect against the 1918 Spanish influenza virus.
"Considering the millions of people who have already been vaccinated against 2009 H1N1 influenza, cross-protection against the 1918 influenza virus may be widespread. Our research indicates that people who were exposed to the virus may also be protected," said Garcia-Sastre. "We look forward to conducting further research on the benefits of the 2009 H1N1 influenza vaccine in protecting against the deadly 1918 Spanish influenza virus."
This research was funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.